Linshom Medical, a TEDCO-backed company, located in Baltimore, MD, was named the winner of the 9th Annual Crab Trap Competition during the BioHealth Capital Region Forum. Linshom impressed the judges with their groundbreaking wearable respiratory monitoring device, the first FDA-cleared technology to deliver an operating room-quality respiratory profile to the patient bedside.
By continuously providing critical metrics such as Respiratory Rate (RR), Tidal Volume (TV), and Minute Ventilation (MV), Linshom’s device predicts respiratory decline up to 70 minutes before an emergency, reducing costly ICU transfers, rapid response activations, and potentially saving lives. Unlike bulky, expensive equipment limited to the ICU or operating rooms, Linshom’s device brings precise, predictive respiratory monitoring to the bedside, addressing a fundamental gap in patient care. Judges praised Linshom for its technological innovation, clear path to market, and the critical need it addresses in modern healthcare, particularly in post-operative and emergency settings.
Talia Feldman, Software Engineer at Linshom, delivered a compelling pitch, showcasing the device’s potential to transform respiratory monitoring across general care floors, emergency rooms, and post-anesthesia care units (PACU), where continuous monitoring is often lacking. The judges were particularly impressed with Linshom’s strong commercialization strategy, the leadership team’s experience, and the device’s significant potential to address unmet needs in the healthcare system. Crab Trap Sponsor Wilson Sonsini was represented by Derrick Rowe, Of Counsel, who presented the giant check for $10,000 to Linshom.
In addition to the Crab Trap prize, Cerillo, a company based in Charlottesville, VA, was awarded $10,000 in CRO services, sponsored by Noble Life Sciences and Accelevir Diagnostics. Eric Mayton, CEO of Cerillo, presented their innovative platform designed to tackle variability in microbiome research.
Cerillo’s platform offers affordable, accessible, and user-friendly tools that minimize inconsistencies in microbial studies, which are crucial for advancing global health initiatives. Their platform addresses the challenges of variability caused by genetics, diet, lifestyle, and methodological differences in microbiome research. By standardizing methodologies and improving statistical approaches, Cerillo aims to enhance the reliability and precision of microbiome-based research and product development, ultimately driving human and environmental health innovation.
Both Linshom Medical and Cerillo stood out among a highly competitive field of finalists, showcasing the diversity of innovation emerging from the BioHealth Capital Region and beyond.
